Reviewing Creative Medical Technology (NASDAQ:CELZ) & Exicure (NASDAQ:XCUR)

Creative Medical Technology (NASDAQ:CELZ) and Exicure (NASDAQ:XCUR) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, earnings and profitability.

Analyst Ratings

This is a summary of recent ratings for Creative Medical Technology and Exicure, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	1	0	1	0	2.00
Exicure	1	0	0	0	1.00

Profitability

This table compares Creative Medical Technology and Exicure’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	N/A	N/A
Exicure	N/A	N/A	N/A

Insider and Institutional Ownership

1.4% of Creative Medical Technology shares are owned by institutional investors. Comparatively, 42.8% of Exicure shares are owned by institutional investors. 1.0% of Creative Medical Technology shares are owned by company insiders. Comparatively, 52.8% of Exicure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Creative Medical Technology and Exicure”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	N/A	N/A	N/A	($2.07)	-0.33
Exicure	N/A	N/A	N/A	($1.32)	-0.81

Exicure is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.

Summary

Exicure beats Creative Medical Technology on 3 of the 5 factors compared between the two stocks.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

About Exicure

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.